120 related articles for article (PubMed ID: 34618220)
21. The Role of Pretreatment
Yao J; Wang Y; Lin Y; Yang Y; Wan J; Gong X; Zhang F; Zhang W; Marks T; Wang S; Jin H; Shan H
Drug Des Devel Ther; 2021; 15():4157-4166. PubMed ID: 34621120
[TBL] [Abstract][Full Text] [Related]
22. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
24. The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
Yao JJ; Jin YN; Lin YJ; Zhang WJ; Marks T; Ryan I; Zhang HY; Xia LP
Radiother Oncol; 2023 Jan; 178():109414. PubMed ID: 36375563
[TBL] [Abstract][Full Text] [Related]
25. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
26. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
27. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
28. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
29. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
30. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
[TBL] [Abstract][Full Text] [Related]
31. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
32. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
33. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
Li XY; Luo DH; Guo L; Mo HY; Sun R; Guo SS; Liu LT; Yang ZC; Yang JH; Qiu F; Sun XS; Wang P; Liu Q; Li JB; Tang QN; Lin C; Yang Q; Liu SL; Liang YJ; Jia GD; Wen DX; Guo CY; Yan JJ; Zhao C; Chen QY; Tang LQ; Mai HQ
J Clin Oncol; 2022 Apr; 40(11):1163-1173. PubMed ID: 34990291
[TBL] [Abstract][Full Text] [Related]
34. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
35. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
Tang SQ; Chen L; Li WF; Chan ATC; Huang SH; Chua MLK; O'Sullivan B; Lee AWM; Lee NY; Zhang Y; Chen YP; Xu C; Sun Y; Tang LL; Ma J
Radiother Oncol; 2022 Feb; 167():179-186. PubMed ID: 34971660
[TBL] [Abstract][Full Text] [Related]
36. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy.
Liu SL; Sun XS; Liu LT; Sun R; Luo DH; Chen QY; Lin HX; Yuan L; Tang LQ; Guo L; Mai HQ
Aging (Albany NY); 2020 Mar; 12(6):4931-4944. PubMed ID: 32221045
[TBL] [Abstract][Full Text] [Related]
37. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).
Dong D; Zhang F; Zhong LZ; Fang MJ; Huang CL; Yao JJ; Sun Y; Tian J; Ma J; Tang LL
BMC Med; 2019 Oct; 17(1):190. PubMed ID: 31640711
[TBL] [Abstract][Full Text] [Related]
39. Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis.
Wang F; Jiang C; Wang L; Yan F; Sun Q; Ye Z; Liu T; Fu Z; Jiang Y
Sci Rep; 2020 Feb; 10(1):2489. PubMed ID: 32051492
[TBL] [Abstract][Full Text] [Related]
40. Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis.
Fangzheng W; Chuner J; Zhimin Y; Quanquan S; Tongxin L; Min X; Peng W; Bin L; Sakamoto M; Yuezhen W; Fengqin Y; Zhenfu F; Yangming J
Oncotarget; 2017 Nov; 8(55):94117-94128. PubMed ID: 29212214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
